FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3161000289> ?p ?o ?g. }

• W3161000289 endingPage "e2111113" @default.
• W3161000289 startingPage "e2111113" @default.
• W3161000289 abstract "Immunotherapy is now a cornerstone of treatment for advanced non-small cell lung cancer (NSCLC), but its uptake and effectiveness among older patients outside clinical trials remain poorly understood.To understand treatment patterns and evaluate the overall survival associated with checkpoint inhibitor immunotherapy, cytotoxic chemotherapy, and combined chemoimmunotherapy for older patients who have advanced NSCLC and Medicare coverage.This retrospective cohort study included Medicare-insured patients in the US aged 66 to 89 years who initiated first palliative-intent systemic therapy for lung cancer between January 1, 2016, and December 31, 2018. Survival follow-up continued through March 31, 2020. A total of 19 529 patients who had advanced lung cancer and were insured by a Medicare fee-for-service plan were included in the analysis.Regimens included pembrolizumab monotherapy (n = 3079), combined platinum-based drug (ie, cisplatin or carboplatin [hereinafter, platinum]) and pemetrexed disodium (n = 5159), combined platinum and a taxane (ie, paclitaxel, nab-paclitaxel, or docetaxel) (n = 9866), and combined platinum, pemetrexed, and pembrolizumab (n = 1425), as ascertained using Medicare claims from the Centers for Medicare & Medicaid Services.The primary outcome was overall survival, which was measured using the restricted mean survival time (RMST) with propensity score adjustment for clinical and sociodemographic characteristics. Median survival was also reported for comparison with outcomes from registrational trials.A total of 19 529 patients (54% male, 46% female; median age, 73.8 [interquartile range, 69.9-78.4] years) were identified for analysis. The uptake of pembrolizumab-containing regimens in the Medicare population was rapid, increasing from 0.7% of first-line treatments in the second quarter of 2016 to 42.4% in the third quarter of 2018. Patients who were older (≥70 years, 2484 [81%]), were female (1577 [51%]), and/or had higher Risk Stratification Index scores (highest quintile, 922 [30%]) were more likely to receive single-agent pembrolizumab than chemotherapy. After propensity score adjustment, pembrolizumab was associated with survival similar to platinum/pemetrexed (RMST difference, -0.2 [95% CI, -0.5 to 0.2] months) or platinum/taxane (RMST difference, -0.7 [95% CI, -1.0 to -0.4] months). Patients receiving platinum/pemetrexed/pembrolizumab chemoimmunotherapy also had adjusted survival similar to those receiving platinum/pemetrexed chemotherapy (RMST difference, 0.5 [95% CI, 0.1-0.9] months). The unadjusted median survival was 11.4 (95% CI, 10.5-12.3) months among patients receiving single-agent pembrolizumab, approximately 15 months shorter than observed among pembrolizumab-treated participants in the KEYNOTE-024 trial. The unadjusted median survival was 12.9 (95% CI, 11.8-14.0) months among patients receiving platinum/pemetrexed/pembrolizumab chemoimmunotherapy, approximately 10 months shorter than observed among platinum/pemetrexed/pembrolizumab-treated participants in the KEYNOTE-189 trial.Immunotherapy has been incorporated rapidly into treatment for patients with advanced NSCLC. However, survival estimates in the Medicare population are much shorter than those reported in registrational trials. These results provide contemporary estimates of survival for older patients with advanced NSCLC treated in routine practice, facilitating patient-centered decision-making." @default.
• W3161000289 created "2021-05-24" @default.
• W3161000289 creator A5029858614 @default.
• W3161000289 creator A5030117790 @default.
• W3161000289 creator A5053129366 @default.
• W3161000289 creator A5063009872 @default.
• W3161000289 creator A5088893766 @default.
• W3161000289 date "2021-05-21" @default.
• W3161000289 modified "2023-10-18" @default.
• W3161000289 title "Association Between First-Line Immune Checkpoint Inhibition and Survival for Medicare-Insured Patients With Advanced Non–Small Cell Lung Cancer" @default.
• W3161000289 cites W1809627231 @default.
• W3161000289 cites W1982488143 @default.
• W3161000289 cites W1990675339 @default.
• W3161000289 cites W2011284201 @default.
• W3161000289 cites W2036193982 @default.
• W3161000289 cites W2045805729 @default.
• W3161000289 cites W2097995306 @default.
• W3161000289 cites W2099725888 @default.
• W3161000289 cites W2104347254 @default.
• W3161000289 cites W2107484016 @default.
• W3161000289 cites W2112121482 @default.
• W3161000289 cites W2121365500 @default.
• W3161000289 cites W2125616358 @default.
• W3161000289 cites W2128035403 @default.
• W3161000289 cites W2152897456 @default.
• W3161000289 cites W2156353875 @default.
• W3161000289 cites W2166662937 @default.
• W3161000289 cites W2198093519 @default.
• W3161000289 cites W2222086386 @default.
• W3161000289 cites W2275737843 @default.
• W3161000289 cites W2331849216 @default.
• W3161000289 cites W2510686645 @default.
• W3161000289 cites W2527905628 @default.
• W3161000289 cites W2529484692 @default.
• W3161000289 cites W2567564314 @default.
• W3161000289 cites W2587359112 @default.
• W3161000289 cites W2622499649 @default.
• W3161000289 cites W2745624257 @default.
• W3161000289 cites W2760699482 @default.
• W3161000289 cites W2781525129 @default.
• W3161000289 cites W2793364080 @default.
• W3161000289 cites W2796582438 @default.
• W3161000289 cites W2804772768 @default.
• W3161000289 cites W2893960509 @default.
• W3161000289 cites W2897422388 @default.
• W3161000289 cites W2910245285 @default.
• W3161000289 cites W2925446385 @default.
• W3161000289 cites W2969539132 @default.
• W3161000289 cites W2992931937 @default.
• W3161000289 cites W3130578256 @default.
• W3161000289 cites W4251210156 @default.
• W3161000289 cites W4255983923 @default.
• W3161000289 doi "https://doi.org/10.1001/jamanetworkopen.2021.11113" @default.
• W3161000289 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8140374" @default.
• W3161000289 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34019086" @default.
• W3161000289 hasPublicationYear "2021" @default.
• W3161000289 type Work @default.
• W3161000289 sameAs 3161000289 @default.
• W3161000289 citedByCount "15" @default.
• W3161000289 countsByYear W31610002892021 @default.
• W3161000289 countsByYear W31610002892022 @default.
• W3161000289 countsByYear W31610002892023 @default.
• W3161000289 crossrefType "journal-article" @default.
• W3161000289 hasAuthorship W3161000289A5029858614 @default.
• W3161000289 hasAuthorship W3161000289A5030117790 @default.
• W3161000289 hasAuthorship W3161000289A5053129366 @default.
• W3161000289 hasAuthorship W3161000289A5063009872 @default.
• W3161000289 hasAuthorship W3161000289A5088893766 @default.
• W3161000289 hasBestOaLocation W31610002891 @default.
• W3161000289 hasConcept C121608353 @default.
• W3161000289 hasConcept C126322002 @default.
• W3161000289 hasConcept C143998085 @default.
• W3161000289 hasConcept C2776256026 @default.
• W3161000289 hasConcept C2776694085 @default.
• W3161000289 hasConcept C2777240266 @default.
• W3161000289 hasConcept C2777511904 @default.
• W3161000289 hasConcept C2777701055 @default.
• W3161000289 hasConcept C2778239845 @default.
• W3161000289 hasConcept C2780030458 @default.
• W3161000289 hasConcept C2780057760 @default.
• W3161000289 hasConcept C2781190966 @default.
• W3161000289 hasConcept C2781451048 @default.
• W3161000289 hasConcept C2908647359 @default.
• W3161000289 hasConcept C530470458 @default.
• W3161000289 hasConcept C71924100 @default.
• W3161000289 hasConcept C99454951 @default.
• W3161000289 hasConceptScore W3161000289C121608353 @default.
• W3161000289 hasConceptScore W3161000289C126322002 @default.
• W3161000289 hasConceptScore W3161000289C143998085 @default.
• W3161000289 hasConceptScore W3161000289C2776256026 @default.
• W3161000289 hasConceptScore W3161000289C2776694085 @default.
• W3161000289 hasConceptScore W3161000289C2777240266 @default.
• W3161000289 hasConceptScore W3161000289C2777511904 @default.
• W3161000289 hasConceptScore W3161000289C2777701055 @default.
• W3161000289 hasConceptScore W3161000289C2778239845 @default.
• W3161000289 hasConceptScore W3161000289C2780030458 @default.
• W3161000289 hasConceptScore W3161000289C2780057760 @default.
• W3161000289 hasConceptScore W3161000289C2781190966 @default.

• next